9 research outputs found
全身性強皮症患者における小腸病変の臨床的意義と小腸カプセル内視鏡を用いた消化管機能評価 1）小腸カプセル内視鏡検査所見は全身性強皮症患者における消化管の状態を反映する 2）全身性強皮症患者における小腸 angioectasia の特徴と治療成績
Get PDF広島大学(Hiroshima University)博士(医学)Doctor of Philosophy in Medical Sciencedoctora
Clinical significance of small-bowel lesions and evaluation of gastrointestinal motility using capsule endoscopy in systemic sclerosis patients 1）Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis 2）Characteristics and Treatment Outcomes of Small-bowel Angioectasia in Systemic Sclerosis Patients: A Retrospective Observational Study
No full textClinical Utility of Emergency Capsule Endoscopy for Diagnosing the Source and Nature of Ongoing Overt Obscure Gastrointestinal Bleeding
No full textExperience with Balloon Dilatation in Crohn’s and Non-Crohn’s Benign Small-Bowel Strictures: Is There a Difference?
No full textExacerbation of Portal Hypertensive Enteropathy after Endoscopic Injection Sclerotherapy for Esophageal Varices
No full textSafety and efficacy of self-expandable metallic stents in malignant small bowel obstructions
No full text
Genomic analysis for the prediction of prognosis in small-bowel cancer.
No full textThe current understanding of clinicopathological features and genomic variants of small-bowel cancer is limited, in part due to the rarity of the disease. However, understanding of these factors is necessary for the development of novel therapeutic agents for small-bowel cancer. Thus, we aimed to identify the clinicopathological features and genomic variants associated with its prognosis and recurrence. We retrospectively examined 24 consecutive patients with primary small-bowel cancer surgically treated between May 2005 and August 2018 and collected 29 tumor specimens. The 29 lesions were subjected to mismatch repair status evaluation, using immunohistochemistry (IHC), and targeted genomic sequencing, after which they were analyzed using a panel of 90 cancer-related genes. IHC revealed that 45% (13/29) of the lesions exhibited deficient mismatch repair. The most common genomic variants in small-bowel cancers were in TP53 (48%, 13/27), followed by KRAS (44%, 12/27), ARID1A (33%, 9/27), PIK3CA (26%, 7/27), APC (26%, 7/27), and SMAD4, NOTCH3, CREBBP, PTCH1, and EP300 (22%, 6/27 each). Overall survival and disease-specific survival of patients with tumor mutational burden (TMB) ≥10 mutations/Mb (n = 17) were significantly better than those of patients with TMB <10 mutations/Mb (n = 6). Additionally, patients with a mutant SMAD4 had poorer recurrence-free survival than those with wild-type SMAD4. Our results suggested that TMB and SMAD4 mutations were associated with the prognosis of small-bowel cancer patients. Thus, cancer genomic analysis could be useful in the search for biomarkers of prognosis prediction in small-bowel cancers
